World J Gastroenterol. 2009 Sep 21;15(35):4356-64. doi: 10.3748/wjg.15.4356.
It is now widely recognized that chronic hepatitis C (CHC) is associated with insulin resistance (IR) and type 2 diabetes, so can be considered a metabolic disease. IR is most strongly associated with hepatitis C virus (HCV) genotype 1, in contrast to hepatic steatosis, which is associated with genotype 3 infection. Apart from the well-described complications of diabetes, IR in CHC predicts faster progression to fibrosis and cirrhosis that may culminate in liver failure and hepatocellular carcinoma. More recently, it has been recognized that IR in CHC predicts a poor response to antiviral therapy. The molecular mechanisms for the association between IR and HCV infection are not well defined. This review will elaborate on the clinical associations between CHC and IR and summarize current knowledge regarding the molecular mechanisms that potentially mediate HCV-associated IR.
目前普遍认为慢性丙型肝炎(CHC)与胰岛素抵抗(IR)和 2 型糖尿病有关,因此可以被视为一种代谢性疾病。IR 与丙型肝炎病毒(HCV)基因型 1 关系最密切,而与肝脂肪变性有关,肝脂肪变性与基因型 3 感染有关。除了糖尿病的已知并发症外,CHC 中的 IR 可预测纤维化和肝硬化的进展更快,最终可能导致肝衰竭和肝细胞癌。最近,人们已经认识到 CHC 中的 IR 预示着对抗病毒治疗的反应不佳。IR 与 HCV 感染之间的关联的分子机制尚不清楚。这篇综述将详细阐述 CHC 和 IR 之间的临床关联,并总结目前关于可能介导 HCV 相关 IR 的分子机制的相关知识。